Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia | Zendy

Christina Konstantopoulos | Zendy; Heather Ribaudo | Zendy; Kathleen Ragland | Zendy; David R. Bangsberg | Zendy; Jonathan Z. Li | Zendy

Open Access

Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia

Author(s) -

Christina Konstantopoulos,

Heather Ribaudo,

Kathleen Ragland,

David R. Bangsberg,

Jonathan Z. Li

Publication year - 2015

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofu119

Subject(s) - medicine , regimen , viremia , pill , ritonavir , hazard ratio , protease inhibitor (pharmacology) , cobicistat , atazanavir , viral load , antiretroviral therapy , human immunodeficiency virus (hiv) , immunology , pharmacology , confidence interval

Episodes of human immunodeficiency virus low-level viremia (LLV) are common in the clinical setting, but its association with antiretroviral therapy (ART) regimen and adherence remains unclear. Antiretroviral therapy adherence was evaluated in participants of the Research on Access to Care in the Homeless cohort by unannounced pill counts. Factors associated with increased risk of LLV include treatment with a protease inhibitor (PI)-based regimen (ritonavir-boosted PI vs nonnucleoside reverse-transcriptase inhibitor: adjusted hazard ratio [HR], 3.1; P = .01) and lower ART adherence over the past 3 months (HR, 1.1 per 5% decreased adherence, adjusted; P = .050). Patients with LLV may benefit from ART adherence counseling and potentially regimen modification.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research